The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Important considerations when treating patients with Ph+ ALL: MRD monitoring, CNS relapse & more
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, gives an overview of a recent publication that highlights important considerations when treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dr Chiaretti notes the importance of measurable residual disease (MRD) monitoring and addressing CNS relapse, suggesting that CAR-T and subsequent allogeneic stem cell transplant may be a viable option for these patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
